Cited 2 times in
Antitumor effects of fotemustine and busulfan against a human neuroblastoma xenograft
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최승훈 | - |
dc.date.accessioned | 2019-11-11T05:23:01Z | - |
dc.date.available | 2019-11-11T05:23:01Z | - |
dc.date.issued | 2000 | - |
dc.identifier.issn | 1021-335X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171829 | - |
dc.description.abstract | We examined whether or not fotemustine, a new nitrosourea derivative, and busulfan, an agent already clinically used, are effective against human neuroblastoma, using a human neuroblastoma xenograft model designated TNB9. The maximum inhibition rate (MIR) of fotemustine against the TNB9 model was 44.6% with a total dose of fotemustine of 75 mg/kg, indicating that fotemustine is not effective against TNB9. The MIR of busulfan against the same model was 26.7% when a total dose of 135 mg/kg was administered orally to nude mice. Busulfan was also suspended in carboxy-methylcellulose, and was administered intraperitoneally. The MIRs were 19.4% and 36. 4% when busulfan was administered intraperitoneally at a total dose of 40 mg/kg and 60 mg/kg, respectively. The total doses of 40 mg/kg and 60 mg/kg did not show any adverse effects on mice, but were found to be ineffective against TNB9, indicating that busulfan might not be an effective chemotherapeutic agent against human neuroblastoma. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | D.A. Spandidos | - |
dc.relation.isPartOf | Oncology Reports | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/pharmacology* | - |
dc.subject.MESH | Antineoplastic Agents, Alkylating/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents, Alkylating/pharmacology* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/pharmacology* | - |
dc.subject.MESH | Busulfan/administration & dosage | - |
dc.subject.MESH | Busulfan/pharmacology* | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Injections, Intraperitoneal | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred BALB C | - |
dc.subject.MESH | Mice, Nude | - |
dc.subject.MESH | Neuroblastoma/drug therapy* | - |
dc.subject.MESH | Nitrosourea Compounds/administration & dosage | - |
dc.subject.MESH | Nitrosourea Compounds/pharmacology* | - |
dc.subject.MESH | Organophosphorus Compounds/administration & dosage | - |
dc.subject.MESH | Organophosphorus Compounds/pharmacology* | - |
dc.subject.MESH | Xenograft Model Antitumor Assays | - |
dc.title | Antitumor effects of fotemustine and busulfan against a human neuroblastoma xenograft | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | H Ikeda | - |
dc.contributor.googleauthor | Y Tsuchida | - |
dc.contributor.googleauthor | J Wu | - |
dc.contributor.googleauthor | N Suzuki | - |
dc.contributor.googleauthor | M Kuroiwa | - |
dc.contributor.googleauthor | S H Choi | - |
dc.contributor.googleauthor | A Morikawa | - |
dc.identifier.doi | 10.3892/or.7.6.1265 | - |
dc.contributor.localId | A04103 | - |
dc.relation.journalcode | J02419 | - |
dc.identifier.eissn | 1791-2431 | - |
dc.identifier.pmid | 11032927 | - |
dc.identifier.url | https://www.spandidos-publications.com/or/7/6/1265 | - |
dc.contributor.alternativeName | Choi, Seung Hoon | - |
dc.contributor.affiliatedAuthor | 최승훈 | - |
dc.citation.volume | 7 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1265 | - |
dc.citation.endPage | 1273 | - |
dc.identifier.bibliographicCitation | Oncology Reports, Vol.7(6) : 1265-1273, 2000 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.